Table 1.

Patient and exam features

Patient/Exam feature	Eligible (N=106)	Final analysis set (N=67)
Age at enrollment (years)
Mean ± standard deviation	48.9 ± 12.0	48.9 ± 12.2
Median (range)	47.5 (24.0–75.0)	49.0 (24.0–75.0)
Number of BI-RADS 3, 4, or 5 lesions, n (%)
1	77 (72.6)	57 (85.1)
2	20 (18.9)	6 (9.0)
3	7 (6.6)	4 (6.0)
4	2 (1.9)	0 (0.0)
Clinical indication for MR imaging, n (%)
Evaluate extent of disease for known breast cancer	47 (44.3)	32 (47.8)
Further evaluation of lesion detected on other imaging	4 (3.8)	2 (3.0)
Short interval follow-up MR imaging	6 (5.7)	4 (6.0)
Screening due to personal history of breast cancer	6 (5.7)	5 (7.5)
Screening due to genetic risk or family history of breast cancer	24 (22.6)	12 (17.9)
Other clinical indication	9 (8.5)	7 (10.4)
Multiple clinical indications	10 (9.4)	5 (7.5)
MR (B₀) field strength (tesla, T), n (%)
1.5 T	42 (39.6)	27 (40.3)
3.0 T	64 (60.4)	40 (59.7)
MR vendor platform, n (%)
Philips 1.5 T	26 (24.5)	14 (20.9)
Siemens 1.5 T	4 (3.8)	3 (4.5)
GE 1.5 T	12 (11.3)	10 (14.9)
Philips 3.0 T	39 (36.8)	26 (38.8)
Siemens 3.0 T	18 (17.0)	10 (14.9)
GE 3.0 T	7 (6.6)	4 (6.0)